04:29 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Defitelio: Ph III started

Jazz began an open-label, international Phase III trial to compare 25 mg/kg/day IV Defitelio plus best supportive care (BSC) vs. BSC alone in about 400 patients ages ≥1 month undergoing HSCT who are at high...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

CX-01: Phase I data

An open-label, U.S. Phase I trial in 12 AML patients showed that induction chemotherapy consisting of cytarabine and idarubicin plus CX-01 as a continuous infusion for 7 days following a bolus led to morphologic complete...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Autoimmune disease; cancer Proteasome In vitro studies identified belactosin A proteasome inhibitors with peptide boronate warheads that could help treat cancer or autoimmune diseases. In...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Defibrotide: Phase I started

Gentium said investigators at Fukushima Medical University began a Japanese Phase I trial to evaluate defibrotide in healthy volunteers. Gentium is providing the compound and technical support to the university. Last month, EMA's CHMP issued...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

Defibrotide: Expanded access program interim data

Interim data from the ongoing, U.S. expanded access program of defibrotide in 104 patients with severe VOD with multi-organ failure showed that 31 patients achieved a complete response and 33 patients survived to day 100...
07:00 , Sep 2, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Thrombosis Tissue factor pathway inhibitor (TFPI) Cell culture and mouse studies suggest that protease-resistant TFPI could help treat thrombosis. In wild-type mice, infusion of...
08:00 , Feb 14, 2005 |  BC Week In Review  |  Clinical News

PGX-100: Start Phase I

ParinGenix will begin this month a placebo-controlled, dose-escalation, U.S. Phase I trial. ParinGenix Inc. , Tucson, Ariz.   Product: PGX-100   Business: Cardiovascular   Molecular target: Elastase ; Cathepsin G   Description: Heparin derivative, 2-O,...